Industry
Biotechnology
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Loading...
Open
16.50
Mkt cap
17M
Volume
117K
High
18.01
P/E Ratio
-3.39
52-wk high
32.55
Low
15.61
Div yield
N/A
52-wk low
5.40
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.